Compare DexCom, Inc. (DXCM) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while Hilton Hotels Corporation Common Stock trades at $323.13 (market cap $74.78B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.7× DexCom, Inc.'s market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | HLT | |
|---|---|---|
Market Cap | $28.06B | $74.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $350.22 |
52-Week Low | $54.84 | $256.75 |
Enterprise Value | $27.03B | $87.27B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Hilton Worldwide (HLT) trades at $325.86, showing stability with no recent price change. The stock exhibits bearish technical signals but maintains strong fundamentals, including consistent revenue growth to $12.04B in 2025 and a net income margin of 12.56%. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 55.1% buy rating. Key developments include brand expansions and partnerships, such as the launch of Undergraduate by Hilton and collaborations with Big Brothers Big Sisters, highlighting ongoing growth initiatives.
The outlook for HLT is cautiously optimistic, driven by solid earnings performance and strategic growth, though elevated debt levels and bearish technical indicators pose risks. Investors should weigh the company's strong market position against potential volatility from macroeconomic factors and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
